Epstein-Barr virus (EBV) is a human herpesvirus associated with a number of malignancies. EBV establishes a latent infection in human B cells in vitro, and infected lymphoblastoid cells proliferate indefinitely as a result of virus activation of cellular signalling pathways. Latently infected cells express a viral oncoprotein called the latent membrane protein-1 (LMP-1). LMP-1 signals both proliferative and survival signals to the infected B cell. The switch from latency to lytic replication is associated with upregulation of an N-terminally truncated LMP-1, called lytic LMP-1 (lyLMP-1). To understand better the relationship between LMP-1 protein function and the virus life cycle, LMP-1 and lyLMP-1 were precisely localized in infected B cells. Immunoelectron microscopy of latently infected cells revealed LMP-1 localized in discrete patches in the plasma membrane. Unexpectedly, immunogold-labelled LMP-1 was found in vesicles budding from the plasma membrane into the extracellular space and in small membrane vesicles accumulating in conditioned medium from infected cells. LyLMP-1 immunolabelling was observed only in B95-8 cells harbouring detectable intracellular virus particles and was abundant in the nuclear membrane early, and in the plasma membrane late, following lytic cycle induction. LyLMP-1 immunoreactivity was also observed at sites of virus budding and associated with intracellular virions, suggesting that lyLMP-1 might be incorporated into cytoplasmic virions when budding through the nuclear membrane.
INTRODUCTION
Epstein-Barr virus (EBV) is a human herpesvirus well known as the aetiologic agent of infectious mononucleosis Niederman et al., 1968) . EBV is associated with many human malignancies, including Burkitt's lymphoma and nasopharyngeal carcinoma (Miller, 1985) . Immunocompromised individuals are at high risk for development of EBV-dependent lymphoproliferative disease (Cannon et al., 1990; Cohen, 1991; Garnier et al., 1989; Ho et al., 1988; Sugden, 1982) . EBV infects primary human B lymphocytes efficiently in vitro and converts them to indefinitely proliferating B lymphoblasts (Sugden, 1989; Sugden & Mark, 1977) . Viral DNA is maintained latently in EBV-immortalized B lymphoblasts, and a small subset of viral genes required for viral genome maintenance and persistent cell proliferation and survival is expressed (Sugden, 1989) . So-called 'tightly latent' lymphoblastoid cell lines, such as the 721 cells used in this study, do not enter the lytic cycle and do not produce progeny virus. 721 cells are an EBV-positive human lymphoblastoid cell line derived from in vitro infection and immortalization of adult peripheral B lymphocytes (Kavathas et al., 1980) . A small percentage of cells within most EBV-positive human lymphoblastoid cell lines support lytic infection. The EBV-positive B lymphoblastoid cell line B95-8, derived from infected marmoset lymphocytes, produces more virus than human lymphoblastoid cell lines and the efficiency of virus production can be increased by treatment with chemical inducers such as phorbol esters (Miller, 1989; Miller & Lipman, 1973) . Herpesvirus capsids, assembled in the nucleus, bud through the inner nuclear membrane and thereby acquire tegument and a primary envelope (Gong & Kieff, 1990; Steven & Spear, 1997) . How the maturing virus particle moves from the perinuclear space to the plasma membrane is not well understood. The primary envelope can fuse with the outer nuclear membrane, resulting in nucleocapsid release into the cytoplasm (Gong & Kieff, 1990) . EBV has also been proposed to leave the perinuclear space via budding through the outer nuclear membrane in vesicles, which then release nucleocapsids into the cytoplasm (Gong & Kieff, 1990; Torrisi et al., 1989) . The virus may acquire its final envelope either by budding through the plasma membrane or by budding into post-Golgiderived vesicles followed by exocytosis of the enveloped virion (Gong & Kieff, 1990) . Thus, a process of nucleocapsid envelopment, de-envelopment and re-envelopment must occur during EBV egress.
EBV encodes two related membrane proteins, latent membrane protein-1 (LMP-1) and lytic LMP-1 (lyLMP-1). The two proteins are differentially expressed during the virus life cycle in vitro (Hudson et al., 1985) . LMP-1 is expressed during latent infection and is essential for human B cell immortalization by EBV (Fennewald et al., 1984; Kaye et al., 1993) . LMP-1's constitutive tumour necrosis factor receptor-associated factor (TRAF)-dependent activity contributes both proliferative and survival signals to the immortalized cell (Eliopoulos & Rickinson, 1998; Izumi et al., 1997; Kilger et al., 1998; Zimber-Strobl et al., 1996) . LMP-1 is a multispanning membrane protein and accumulates at the surface of the infected cell and in intracellular membranes (Mann et al., 1985) . Immunofluorescent analysis of the subcellular localization of LMP-1 in a variety of cell types, including B cells, reveals patched staining at the surface and within intracellular membrane compartments (Liebowitz et al., 1986; Mann et al., 1985) . LMP-1 may signal, possibly as an oligomer, from lipid microdomains (lipid rafts) in the plasma membrane (Higuchi et al., 2001; Kaykas et al., 2001) .
LyLMP-1 is categorized as a late lytic-cycle protein in permissive B95-8 cells (Hudson et al., 1985) . LyLMP-1 encodes the C-terminal 258 aa of LMP-1 and thus is comprised of the fifth and sixth transmembrane domains and the C terminus of LMP-1. Although lyLMP-1 retains the intracellular signalling domain of LMP-1, it does not bind TRAFs nor does it activate TRAF-dependent signalling pathways Erickson & Martin, 2000; Huen et al., 1995; Mitchell & Sugden, 1995; Wang et al., 1988a, b) . LyLMP-1 can inhibit LMP-1 signalling to NF-kB and JNK when the two proteins are coexpressed at levels mimicking those observed in phorbol 12-tetradecanoate 13-acetate (TPA) and butyrate (TPA/ butyrate)-induced B95-8 cells. Inhibition does not result from the sequestration of lyLMP-1 of critical TRAF proteins nor from disruption by LMP-1 oligomers (Erickson & Martin, 1997 . Immunofluorescent studies of infected B cells show that, unlike LMP-1, lyLMP-1 staining is not patched in cell membranes but is diffuse and localized to intracellular membranes (Wang et al., 1988a, b) . LyLMP-1 immunoreactivity has been localized to cell-free, extracellular EBV virions in B95-8 cell supernatants (Erickson & Martin, 1997 ).
More precise localization of LMP-1 proteins in EBVinfected B cells was undertaken to reveal clues to their function in the EBV life cycle in general and to models of lyLMP-1 inhibition of LMP-1 signalling. Here we report the ultrastructural localization of LMP-1 and lyLMP-1 determined by immunoelectron microscopy of rapidly frozen, latently infected, B lymphoblastoid cells and permissive B95-8 cells. LMP-1 immunoreactivity was clustered at the surface of 721 cells, in cell surface vesicles budding to the outside of the cell and in small vesicles accumulating in 721 cell culture medium. LyLMP-1 labelling was detected only in B95-8 cells actively producing virus and was concentrated in nuclear membranes early when virus particles were in the nucleus, and in cytoplasmic and plasma membranes late when virus particles accumulated in the cytoplasm. Finally, we found lyLMP-1 immunoreactivity associated with both intracellular and extracellular enveloped virions.
METHODS
Cells. 721 cells are a human, tightly latent, EBV-positive lymphoblastoid cell line and do not enter the lytic cycle or produce virus (Kavathas et al., 1980) . B95-8 cells are an EBV-positive B cell line transformed in vitro with B95-8 virus. B95-8 cells release virus particles spontaneously and the number of cells producing virus is increased by treatment with TPA/butyrate (Miller et al., 1972) .
Lytic cycle induction. B95-8 cells were grown to saturation (10 6 cells ml
21
), treated with 20 ng TPA ml 21 and 3?5 mM sodium butyrate (TPA/butyrate) for 72 h and harvested by centrifugation. Cell pellets were processed for Western blot analysis or electron microscopy (EM).
Antibodies. The primary antiserum (anti-LMP-1) used for immunochemistry was raised in rabbits against the LMP-1 C terminus fused to glutathione S-transferase and affinity-purified; anti-LMP-1 antiserum recognizes both LMP-1 and lyLMP-1. 72A1 is a mouse monoclonal antibody that recognizes the EBV lytic cycle protein gp350/220 (a gift from L. Hutt-Fletcher). Secondary antibodies include: alkaline phosphatase-conjugated anti-rabbit IgG (Sigma); FITC-conjugated anti-rabbit IgG (Sigma); horseradish peroxidaseconjugated anti-rabbit IgG (Promega); goat anti-rabbit IgG conjugated to 10 or 15 nm gold particles; and goat anti-mouse IgG/IgM conjugated to 15 nm gold particles (Ted Pella).
Western blot analysis. Whole cell lysates and purified membrane fractions were analysed by SDS-PAGE (10 % gels) and Western blot using anti-LMP-1 antiserum, as described previously (Coffin et al., 2001; Erickson & Martin, 1997) .
Immunofluorescence analysis. Cells were fixed on coverslips and stained for LMP-1, as described previously (Coffin et al., 2001 ).
High-pressure freezing. Cell cultures of 10 5 -10 6 cells ml 21 were harvested by centrifugation and resuspended in a cryoprotectant solution of 150 mM mannitol in RPMI medium supplemented with 10 % calf serum. Pelleted cells were transferred into a brass specimen carrier and inserted into the BAL-TEC HPM-010 high-pressure freezer (Technotrade International) (Giddings et al., 2001) . Frozen samples were transferred to liquid nitrogen and maintained at 2196 uC until freeze-substitution.
Freeze-substitution and embedding in Lowicryl HM20. Highpressure frozen samples were freeze-substituted in 0?25 % glutaraldehyde/0?1 % uranyl acetate in acetone at 280 uC for 3 days and incubated at 220 uC for 1 day. Fixed and dehydrated cells were then infiltrated with a series of acetone/Lowicryl HM20 mixtures at 220 uC until 100 % HM20 resin was attained. After several changes with fresh HM20 at 220 uC, samples were loaded into plastic embedding capsules and the resin was polymerized by exposure to UV at 250 uC (Giddings et al., 2001 ).
Freeze-substitution and embedding in Epon-Araldite. Frozen cells were transferred to freeze-substitution medium composed of 0?5 % glutaraldehyde/0?05 % tannic acid in acetone. Samples were stored at 280 uC for 2 days, rinsed in acetone at 280 uC and transferred to 2 % osmium tetroxide in acetone at the same temperature. Specimens were warmed up gradually to room temperature over 24 h and then rinsed with acetone. Samples were then infiltrated with Epon resin.
Immunolabelling of freeze-substituted samples. Sections, 50-60 nm thick, were collected on Formvar-coated nickel grids. Nonspecific antibody binding was blocked by incubation in 2 % non-fat dry milk in PBS/0?1 % Tween 20 (PBST). Samples were incubated in primary antibody (1 : 20 in blocking buffer) and then rinsed with PBST. Grids were transferred to secondary antibody (1 : 5 or 1 : 20 in PBST), then rinsed in PBST followed by water. Following antibody labelling, samples were stained with 2 % uranyl acetate in either water or 70 % methanol/water and post-stained with Reynold's lead citrate. Samples were analysed at 80 kV on a Philips CM10 transmission electron microscope.
Surface immunolabelling of intracellular and extracellular virions. B95-8 cells were treated with TPA/butyrate for 96 h and harvested by centrifugation. Cell pellets were resuspended and incubated with anti-LMP-1 antiserum (1 : 10) in blocking solution (2 % BSA/16 PBS) for 45 min on ice. Cells were resuspended in blocking solution and incubated in goat anti-rabbit secondary antibody conjugated to gold (1 : 5) in blocking solution for 45 min on ice. After washing with blocking solution, cells were fixed with Karnovsky's fixative (5 % glutaraldehyde/4 % formaldehyde) overnight, followed by fixation with 1 % osmium tetroxide. Finally, specimens were dehydrated gradually with increasing concentrations of ethanol mixtures up to 100 % ethanol, then embedded in Epon. Blocks were sectioned, stained and visualized by EM as described above.
Fractionation of 721 cell culture medium. 721 cells were washed twice in PBS, plated at 4610 5 cells ml 21 in~35 ml RPMI medium supplemented with 10 % calf serum and grown for 24-48 h. Differential centrifugation of 721 cell supernatants was performed essentially as described (Raposo et al., 1996) . Cells were removed by centrifugation at 300 g and the medium was centrifuged sequentially at 300 g (10 min), 1200 g (twice for 10 min), 10 000 g (30 min), 70 000 g (1 h) and 100 000 g (1 h) (10 000, 70 000 and 100 000 g spins were performed in an SW27 rotor). Pellets were resuspended in 20 ml PBS and recentrifuged at 100 000 g for 1 h. Final pellets were resuspended in 25 ml PBS. Samples were diluted 1 : 1 with 46 SDS sample buffer and one-quarter of each pellet was analysed by Western blot with anti-LMP-1 antiserum, as described above. The pellet from the 70 000 g spin was analysed by sucrose gradient centrifugation as described below.
Sucrose density centrifugation of the 70 000 g pellet from 721 cell supernatants. Sucrose gradient centrifugation was performed as described previously (Raposo et al., 1996) . Briefly, the 70 000 g pellet [from fractionated cell medium (above)] was resuspended in 2?5 M sucrose/20 mM HEPES/NaOH, pH 7?2. A linear sucrose gradient (2-0?25 M sucrose/20 mM HEPES/NaOH, pH 7?2) was layered on top of the resuspended pellet and centrifuged in an SW27 rotor at 100 000 g for 15 h. Fractions were taken from the top of the gradient (1862 ml), diluted with 2 ml PBS and recentrifuged for 1 h at 200 000 g in an SW50.1 rotor. Resulting pellets were analysed by EM (see below) or SDS-PAGE. For SDS-PAGE, pellets were resuspended in 100 ml 46 SDS sample buffer and 15 ml of each fraction was analysed by SDS-PAGE, as described above. For EM analysis, pellets were resuspended in PBS and processed as described below.
Immunoelectron microscopic analysis of the 70 000 g pellet.
Pellets from sucrose gradient fractions 7-12 were resuspended and pooled in 30 ml PBS. Pooled material was pelleted in an SW27 rotor at 70 000 g for 1 h and the resulting pellet was resuspended in 20 ml 0?02 % sodium azide/PBS, fixed immediately with 2 % paraformaldehyde, placed on copper grids and air-dried. Grids were blocked with 1 % BSA/PBS for 30 min, incubated in anti-LMP-1 antiserum for 45 min and labelled with secondary antibody (antirabbit antibody conjugated with 15 nm gold) for 45 min. Grids were stained with 1 % uranyl acetate and visualized with a Philips Technai F20 transmission electron microscope operating at 80 kV.
RESULTS

Subcellular distribution of LMP-1 in latently infected lymphoblastoid cells
We chose to examine the subcellular localization of LMP-1 in the latently infected lymphoblastoid cell line 721. These cells are tightly latent, immortalized by EBV, and do not produce virus. Importantly, 721 cells express the full-length form of LMP-1, but not lyLMP-1, and thus can be used to localize LMP-1 in the absence of lyLMP-1. LMP-1 expression in 721 cells was confirmed by Western blot analysis of cell extracts (Fig. 1A ) and immunofluorescence analysis of fixed cells (not shown). LMP-1 staining in fixed 721 cells was specific, as shown by the absence of positive staining in cells stained without primary antibody and in the EBVnegative B lymphoma cell line DG75 (not shown). The majority of 721 cells were positive for LMP-1. These results identified 721 cells as a feasible cell line for EM studies to localize LMP-1.
Immunoelectron microscopic analysis of high-pressure frozen 721 cells revealed LMP-1 immunoreactivity localized to patches or clusters in the plasma membrane, as indicated by clustering of gold particles at the cell surface (Fig. 1B) . LMP-1 labelling was also observed to a lesser extent, and was unclustered, in cytoplasmic membranes and the nuclear membrane (not shown). Unexpectedly, we also frequently observed patched LMP-1 labelling in plasma membrane protrusions, or buds, extending to the outside of the cell (Fig. 1C) . Immunogold labelling in cell surface protrusions was denser than that observed in other regions of the plasma membrane. These protrusions could represent plasma membrane 'budding' into the extracellular space. This staining pattern was not observed when sections were stained in the absence of primary antibody (not shown), demonstrating that the immunogold-labelling pattern was specific for LMP-1.
Identification of LMP-1 in plasma membrane protrusions
To determine if LMP-1-enriched plasma membrane protrusions represented a stage in the process of plasma membrane budding, we asked if LMP-1 protein accumulated in the supernatant of 721 cells. Conditioned media from 721 cells was fractionated by differential centrifugation and fractions were assayed by Western blot for LMP-1 ( Fig. 2A) . Full-length LMP-1 was found in the cell pellet (300 g spin) and 1200 g pellets containing broken cell debris. Importantly, LMP-1 was found in the pellet from the 70 000 g spin. Previous work has demonstrated that 70 000 g pellets harvested from conditioned medium from EBV-positive B lymphoblastoid cells contain small membrane vesicles of 60-80 nm in diameter, called exosomes, which could activate T cells (Raposo et al., 1996) . The LMP-1 fractionating with the 70 000 g pellet may be contained in exosomes or perhaps in small membrane vesicles derived from the plasma membrane. To determine if the LMP-1 immunoreactivity in the 70 000 g pellet was membrane bound, material from the 70 000 g pellet was analysed by sucrose gradient centrifugation. LMP-1 protein floated to an equilibrium density of 1?13 g ml
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, confirming its association with membrane vesicles (Fig. 2B) . Pelleted material from fractions 7-12 (corresponding to densities of 1?121-1?213 g ml
) was analysed by immunoelectron microscopy to determine the size and homogeneity of LMP-1-containing vesicles. LMP-1 labelling was observed in small membrane vesicles of fairly homogeneous size, with an average diameter of~80 nm (Fig. 2C) . Thus, LMP-1-containing vesicles exhibit properties very similar to exosomes isolated from supernatants of EBV-immortalized lymphoblastoid cell lines (Escola et al., 1998; Raposo et al., 1996) .
Localization of LMP-1 in permissive B95-8 cells
Using conditions optimized in 721 cells for immunogold LMP-1 labelling, LMP-1 proteins were localized in the virus-producing cell line B95-8. B95-8 cells are a marmoset B cell line immortalized in vitro by infection with EBV (Miller & Lipman, 1973) . As few as 1 % of cells in a population spontaneously produce virus, and treatment with lytic-cycle inducers, like TPA/butyrate, increases the efficiency of virus production so that up to 15 % of cells enter the lytic cycle and release virus (our unpublished observations). Full-length LMP-1 was detectable by Western blot analysis in populations of uninduced B95-8 cells (Fig. 1A) . If the fraction of uninduced B95-8 cells spontaneously in the lytic cycle is high, lyLMP-1 can be detected as well; the ratio of LMP-1 to lyLMP-1 in uninduced B95-8 cells is always greater than one (our unpublished observations). LyLMP-1 was undetectable in the uninduced B95-8 population (Fig. 1A) . TPA/butyrate treatment increased the level of expressed lyLMP-1 but had no effect on full-length LMP-1 levels, such that by 72 h postinduction, the ratio of LMP-1 to lyLMP-1 was significantly less than one (Fig. 1A) (Baichwal & Sugden, 1987; Erickson & Martin, 1997) . Given this pattern of LMP-1 expression, we next determined the subcellular location of LMP-1 proteins in uninduced B95-8 cells.
Cell pellets from uninduced B95-8 cells were examined. No specific pattern of immunolabelling could be detected in uninduced B95-8 cells. Nonspecific labelling with gold particles was observed, at very low density, throughout the cell (not shown). Qualitative Western blot analysis revealed that uninduced B95-8 cells expressed significantly less full-length LMP-1 than did 721 cells on a population level (Fig. 3) . Therefore, the lack of specific LMP-1 labelling in uninduced B95-8 cells resulted from the fact that full-length LMP-1 levels were below the limit of detection of our immunogold-labelling method. Localization of fulllength LMP-1 in B95-8 cells was, therefore, not possible.
Localization of lyLMP-1 in TPA/butyrate-induced B95-8 cells
Our inability to detect full-length LMP-1 in uninduced B95-8 cells was fortuitous in that it allowed lyLMP-1 labelling in TPA/butyrate-treated cells without the simultaneous labelling of full-length LMP-1 (our antiserum recognizes shared epitopes in both viral proteins). LyLMP-1, but not full-length LMP-1, is upregulated by lytic-cycle induction (Fig. 1A) . Thus, any specific labelling observed in TPA/butyrate-induced B95-8 cells reflected lyLMP-1 localization, since LMP-1 levels did not change with TPA/ butyrate induction.
In contrast to uninduced B95-8 cells, specific labelling was observed in B95-8 cells treated with TPA/butyrate for . (C) Fractions 7-12 from the sucrose gradient in (B) were pooled and pelleted as described in Methods. The resulting pellet was fixed in 2 % paraformaldehyde, stained with anti-LMP-1 antiserum and 15 nm gold-conjugated anti-rabbit Ig, and uranyl acetate, and visualized by EM. Bar, 80 nm. 72 h (Figs 4 and 5) . Immunolabelling was observed in the nuclear membrane, plasma membrane and, to a lesser extent, in cytoplasmic membranes. The pattern of gold labelling was distinct from that observed for LMP-1 in 721 cells in that it was rarely organized in 'patches' or clusters in the membrane (Figs 4 and 5) . Importantly, specific labelling was observed only in cells producing virus (i.e. cells in which intracellular virus was detected by EM) ( Table 1) . The lack of labelling in uninduced cells, the restriction of labelling to cells producing virus, and the lack of similarity in labelling pattern between TPA/butyrateinduced B95-8 cells and 721 cells indicated that immunogold labelling in TPA/butyrate-induced B95-8 cells reflected lyLMP-1, and not full-length LMP-1, localization.
LyLMP-1 labelling was abundant in the nuclear membrane at early stages of virus production when the nuclear membrane was still intact and capsids were visible in the nucleus (Fig. 4) . Later, when virus particles accumulated in the cytoplasm, lyLMP-1 labelling became more abundant in the plasma membrane and cytoplasm (Fig. 5) . We also observed labelling at the site of virus budding through the nuclear membrane, suggesting a potential role for lyLMP-1 in virus egress from the nucleus (Fig. 5) . It is important to note that TPA/butyrate treatment does not result in synchronous activation of the lytic cycle in an induced B95-8 cell population. Thus, cells at various stages of virus production will be present in cultures treated for 72 h with TPA/butyrate. The distribution of gold labels in the nuclear membrane versus plasma membrane was quantified. Out of 72 cells counted, 13 % were positive for virus and 87 % were negative (no virus particles found inside the cell). Of   Fig. 4 . LyLMP-1 labelling in the nuclear membrane of virus-producing B95-8 cells. B95-8 cells treated for 72 h with TPA/ butyrate were prepared for immunoelectron microscopy as described in the legend to Fig. 1 . LyLMP-1 (arrowheads) is localized in the nuclear membrane at early stages of virus production when the nuclear membrane is still intact and nucleocapsids are in the nucleus. High magnification showing gold labelling of the nuclear membrane but not the plasma membrane (A). Nucleocapsids are visible in the nucleus along the nuclear membrane (A, B) . PM, Plasma membrane; C, cytoplasm; NM, nuclear membrane; N, nucleus; bars, 100 nm. . The open arrowhead points to a virus particle budding from the nuclear membrane. The nuclear membrane near the budding virion is labelled with gold. Note: TPA/butyrate treatment results in asynchronous cycle induction of the lytic cycle in B95-8 cells; cells in various stages of virus production will be present 72 h postinduction. PM, plasma membrane; C, cytoplasm; N, nucleus; bars, 100 nm. Table 1 . TPA/butyrate-induced B95-8 cells TPA/butyrate-induced B95-8 cells were processed for immunoelectron microscopy as described in the legend to Fig. 1 . The number of cells with visible intracellular virus particles were scored, as well as the number of virion-positive and virion-negative cells with gold labels in the plasma membrane or nuclear membrane. Of the 72 cells counted, 9 were virion positive and 63 were virion negative (consistent with Erickson & Martin, 1997) . Among the virus-positive cells, gold label was obviously localized in nuclear and plasma membranes, whereas only 4 and 6 % of virion-negative cells had gold label in the nuclear and plasma membranes, respectively. the virus-positive cells, 100 % showed lyLMP-1 labelling of nuclear and plasma membranes. Of the 63 virus-negative cells counted, only three cells (4 %) had label in the plasma membrane and four cells (6 %) had label in the nuclear membrane (Table 1) .
Morphological examination of cytoplasmic virus particles revealed that many resembled nucleocapsids found inside the nucleus. To enhance morphological preservation of the viral envelope and to determine if cytoplasmic virus particles were naked nucleocapsids, TPA/butyrate-induced B95-8 cells were fixed with osmium after high-pressure freezing and embedded in Epon resin (Fig. 6) . Extracellular enveloped virions ranged in size from 100 to 150 nm in diameter, whereas nuclear and many cytoplasmic nucleocapsids were generally less than 100 nm in diameter. These observations suggest that many virus particles in the cytoplasm lacked envelopes and are consistent with a process of rapid de-and re-envelopment of the nucleocapsid during virus egress, as suggested previously (Gong & Kieff, 1990) .
LyLMP-1 labelling in intracellular and extracellular virions
LyLMP-1 immunoreactivity is associated with extracellular virus particles in cell-free B95-8 supernatants (Erickson & Martin, 1997) . A major goal of our immunoelectron microscopy localization study was to visualize lyLMP-1 in intracellular virions to extend our previous studies and to identify the point during the lytic cycle that lyLMP-1 becomes virion-associated. High-pressure freezing and immunolabelling, followed by embedding in Lowicryl and sectioning, revealed little or no labelling of intracellular virions (not shown). Cells were labelled with anti-gp350/ 220 antibody 72A1 as a control for plasma membrane immunogold labelling. gp350/220 is the most abundant viral glycoprotein localized in the viral envelope and plasma membrane of virus-producing cells (Gong & Kieff, 1990) . Although abundant immunogold labelling was observed in the plasma membrane, no labelling was observed in extracellular (or intracellular) enveloped virions (not shown). The failure to label virions may be explained by several factors. The concentration of lyLMP-1 in extracellular virions is estimated to be~100 molecules per virion (Erickson & Martin, 1997) and the surface area of the virus envelope is small compared to that of the nuclear and plasma membranes. The resin used for embedding provides a significant barrier to antibody access to antigen and embedding and sectioning for immunoelectron microscopy dictates that only a fraction of the virus particle surface will be accessible to antibody in any given section. A combination of these factors likely contributed to the inefficiency of virion labelling by anti-LMP-1 and antigp350/220 antibodies.
To confirm that lyLMP-1 was virion-associated in cell samples used for immunogold labelling (above), released virus in cell-free supernatants was labelled and stained as described previously (Erickson & Martin, 1997) . Negative staining confirmed our previous findings that lyLMP-1 is associated with virions in TPA/butyrate-induced B95-8 supernatants (not shown; Erickson & Martin, 1997) . To facilitate antibody access to antigen, the cell sample was embedded after antibody incubation (surface labelling). Intact TPA/butyrate-induced B95-8 cells were incubated with anti-LMP-1 antiserum, fixed with osmium, embedded in Epon and processed for EM analysis (see Methods). Data shown in Fig. 7 are from B95-8 cells treated with TPA/ butyrate for 96 h. These cells are actively producing virus and are quite fragile and leaky. Therefore, the primary antisera presumably gained access to intracellular sites by leakage. This approach clearly revealed lyLMP-1 labelling of intracellular and extracellular virions and suggested that our failure to visualize labelled intracellular virions using high-pressure freezing and immunolabelling was due in part to problems with sample preparation (Fig. 7A, B) . These results suggest lyLMP-1 may be incorporated into cytoplasmic virions when budding through the nuclear membrane and into extracellular virions when budding through the plasma membrane.
DISCUSSION
Subcellular localization of LMP-1 proteins has been investigated using immunofluorescence analysis and biochemical fractionation methods (Erickson & Martin, 1997; Liebowitz et al., 1986; Mann et al., 1985) . Recently, LMP-1 has been colocalized by confocal microscopy with lipid raft markers (Kaykas et al., 2001) . While these approaches reveal overall subcellular compartmentalization of proteins, they lack the resolution to allow precise localization of proteins within membrane compartments or virus particles. We took advantage of the high resolution of EM because a major goal of these studies was to localize lyLMP-1 in intracellular virions.
LMP-1 localization in latently infected lymphoblastoid cells
LMP-1, not surprisingly, was localized primarily in the plasma membrane of latently infected lymphoblastoid cells (Fig. 1B) . LMP-1 localization in clusters at the plasma membrane is consistent with its lipid raft localization. However, LMP-1 labelling in plasma membrane 'protrusions' (Fig. 1C) and in 80 nm vesicles in conditioned medium (Fig. 2C) was unexpected. The size of LMP-1-positive vesicles is consistent with LMP-1 being shed into the extracellular space via exosomes or microvesicles. Interestingly, Dukers et al. (2000) reported, but did not characterize, LMP-1 immunoreactivity in conditioned medium from EBV-positive lymphoblastoid cells. LMP-1 turns over rapidly in 721 cells with a half-life of 2 h (Baichwal & Sugden, 1987) . LMP-1 shedding with the plasma membrane, or LMP-1 secretion in exosomes, may contribute to its observed rapid turnover in these cells. LMP-1 expression must be tightly regulated in EBV-positive lymphoblastoid cells since upwards variation in levels of expression is incompatible with continued cell proliferation (Floettmann et al., 1996; Hammerschmidt et al., 1989; Kaykas & Sugden, 2000) . Thus, LMP-1 shedding, or secretion in exosomes, could allow the cell to regulate levels of LMP-1 accumulation. Alternatively, the presence of LMP-1 in extracellular vesicles may serve an immunoregulatory function, as suggested by the observed immunosuppressive effect of purified recombinant LMP-1 protein, or LMP-1-derived peptides, on T cell activation (Dukers et al., 2000) . LMP-1 containing vesicles may deliver LMP-1 or LMP-1 fragments by fusion with infiltrating T cells. An immunosuppressive function is consistent with the cytostatic activity of LMP-1 but is at odds with the observed T cell stimulation induced by EBV-positive lymphoblastoid cellderived exosomes (Raposo et al., 1996) . Immunoelectron microscopy localization in budding plasma membrane protrusions (Fig. 1C) argues against the presence of LMP-1 in secreted exosomes, but instead supports the model that LMP-1 is contained in shed plasma membrane microvesicles. However, intracellular membrane structures, such as multivesicular bodies (MVBs), may not have been preserved during the immunolabelling fixation procedure, so the possibility that LMP-1 is secreted in MVB-derived exosomes must also be considered.
LyLMP-1 localization in virus-producing B95-8 cells Because of its relatively low level of expression at the single-cell level, full-length LMP-1 labelling was undetectable in uninduced B95-8 cells despite the detection of LMP-1 immunoreactivity in B95-8 cells by Western blot analysis ( Figs 1A and 3) . LyLMP-1, and not LMP-1, is dramatically upregulated upon lytic-cycle induction in B95-8 cells (Baichwal & Sugden, 1987; Hudson et al., 1985) and is easily detected by Western blot (Fig. 1A) . Upregulated lyLMP-1 is concentrated in the 12-15 % of cells undergoing the lytic cycle (Table 1) , thus facilitating its detection by immunoelectron microscopy at the single-cell level. Restriction of lyLMP-1 labelling to virus-producing cells indicates that lyLMP-1 upregulation upon lytic-cycle induction occurs only in cells in the lytic cycle and does not result from general activation of cell-signalling pathways by TPA/butyrate. LyLMP-1 labelling was abundant in the nuclear membrane at early stages of the lytic cycle (Fig. 4) , and in plasma membranes, cytoplasm and at the site of virus budding from nuclear membranes at later stages of virus production (Fig. 5) . Together, these results suggest a role for lyLMP-1 in virus egress from the cell and/or in lytic cycle progression. The ability of lyLMP-1 to negatively regulate LMP-1 activation of NF-kB (Erickson & Martin, 2000) further supports a model in which lyLMP-1 contributes to lytic cycle progression, particularly given recent results showing that the activation of NF-kB by LMP-1 plays a role in preventing lytic cycle activation (Adler et al., 2002; Prince et al., 2002) . Thus, lyLMP-1 may contribute to lytic cycle progression both at a structural level and at the level of regulation of cell signalling.
LyLMP-1 immunoreactivity is associated with extracellular virions in B95-8 virus supernatants (Erickson & Martin, 1997) . We have extended these findings by showing the association of lyLMP-1 with intracellular virus particles in the cytoplasm. First attempts to label intracellular and extracellular virus particles with both anti-LMP-1 sera and anti-gp350/220 antibody in thin sections embedded in Lowicryl resin were unsuccessful. However, surface labelling of intracellular virions revealed abundant immunogold labelled lyLMP-1 in intracellular virions (Fig. 7B) . The presence of lyLMP-1 in intracellular virions suggests lyLMP-1 is incorporated into virions as they bud through cellular membranes. Our observations are consistent with previous results suggesting de-envelopment of virus while budding through the outer nuclear membrane followed by re-envelopment upon budding through cytoplasmic or plasma membranes (Gong & Kieff, 1990) . Virus egress from B95-8 cells is likely to involve a process of de-envelopment and re-envelopment in the cytoplasm as the virus particle transits through the endoplasmic reticulum, Golgi and cytoplasmic vesicles (Gong & Kieff, 1990; Wild et al., 2002) . The process of de-and re-envelopment could culminate in the incorporation of lyLMP-1 into the virion upon final budding through the plasma membrane.
